Has Hims & Hers' GLP-1 Gamble Backfired Permanently

Key Takeaways

• Hims & Hers (HIMS) faces significant regulatory and legal headwinds after its aggressive foray into compounded GLP-1 weight-loss drugs, leading to a sharp stock decline.
• The company’s rapid withdrawal of its $49 semaglutide pill, coupled with a patent infringement lawsuit from Novo Nordisk and FDA scrutiny, casts a shadow over its growth strategy.
• While HIMS is pivoting towards longevity and diagnostics, the core telehealth business must demonstrate resilience and compliant growth to regain investor confidence amidst heightened operational risks.

Has Hims & Hers' GLP-1 Gamble Backfired Permanently?

Hims & Hers Health (NYSE: HIMS) recently found itself in the crosshairs of both regulatory bodies and pharmaceutical giants, a situation that has severely tested its growth narrative and sent its stock price tumbling. The company's ambitious move to offer a compounded version of semaglutide, the active ingredient in blockbuster GLP-1 weight-loss drugs like Wegovy, for a mere $49 per month was initially met with investor enthusiasm. However, this aggressive pricing strategy quickly triggered a fierce backlash, culminating in a patent infringement lawsuit from Novo Nordisk and a stern warning from the U.S. Food and Drug Administration (FDA).

The immediate fallout was stark: HIMS shares plunged nearly 20% on February 9, 2026, dropping to $19.33 within a single trading day, and currently trade at $15.63. This dramatic reversal highlights the inherent risks of operating in the highly regulated pharmaceutical space, especially when challenging established players with patent-protected products. The company's quick withdrawal of its compounded GLP-1 pill, just days after its launch, signals a recognition of the escalating legal and regulatory pressure.

This episode is more than just a product setback; it represents a critical juncture for Hims & Hers. The company, known for its direct-to-consumer telehealth model across categories like hair loss and sexual health, had positioned GLP-1s as a significant new growth pillar. With the $49 pill thesis now defunct, investors are left questioning the company's ability to navigate complex regulatory landscapes and its long-term strategy for high-demand, high-margin categories. The market's reaction underscores how quickly sentiment can shift when a core business initiative faces such formidable legal and governmental opposition.

What Are the Legal and Regulatory Stakes for HIMS?

The legal and regulatory landscape for Hims & Hers has become significantly more challenging, moving beyond mere competitive pressure to direct enforcement actions. Novo Nordisk's lawsuit is not just about market share; it seeks a permanent ban on HIMS selling compounded versions of its drugs that allegedly infringe on patents, and it aims to recover damages. This legal challenge targets the very foundation of HIMS's GLP-1 strategy, specifically the use of semaglutide, which is protected by U.S. patents through 2032.

Adding to the legal woes, the FDA has taken a strong stance, signaling its intent to restrict access to active pharmaceutical ingredients for non-FDA-approved compounded drugs that are mass-marketed. The Department of Health and Human Services even referred Hims & Hers to the Department of Justice for a probe into potential violations of the Federal Food, Drug, & Cosmetic Act (FD&C Act). Such a referral carries serious implications, including civil penalties, product seizures, and even potential criminal charges for responsible executives under Title 18.

The core of the dispute revolves around the "compounding loophole." While compounding is permitted for individual patient needs (e.g., allergies, specific dosages) or when approved medicines are in short supply, Novo Nordisk argues that its GLP-1 drugs are no longer on the FDA's shortage list. This removes the primary justification for mass compounding. HIMS's defense, that its versions are "personalized" in dosage, is being challenged as a pretext for illegal mass production. The outcome of this litigation and regulatory scrutiny will not only determine HIMS's future in the GLP-1 market but could also set a precedent for other telehealth providers relying on similar compounding practices.

How Will This Impact HIMS's Growth Trajectory and Financials?

The abrupt halt of Hims & Hers' compounded GLP-1 pill offering will undoubtedly impact its near-term growth trajectory and financial outlook. The company had projected its weight loss business to generate $725 million in revenue in 2025, a figure that now seems ambitious given the withdrawal of commercially available semaglutide dosages after Q1 2025. While HIMS reported impressive revenue growth of 69% to $1.48 billion in 2024 and achieved its first full year of GAAP profitability with a net income of $126.0 million, the GLP-1 segment was a key driver of this momentum.

Analyst sentiment has already shifted, with Citi analysts cutting their price target for HIMS to $16.50 from $30.00 and maintaining a Sell rating, citing the "risky and aggressive" GLP-1 launch. Bank of America also lowered its price target to $21.00 from $26.00, reiterating an Underperform rating. The company's P/E ratio of 26.44 (TTM) still appears stretched compared to the wider U.S. Healthcare group's average, suggesting that the market had priced in significant future growth, much of which was tied to the now-stalled GLP-1 expansion.

The financial implications extend beyond lost revenue potential. HIMS will likely incur substantial legal defense costs as it battles Novo Nordisk in court. Furthermore, heightened compliance costs and potential product reformulation efforts could compress margins across its compounded drug offerings. While the company's overall revenue growth was strong at 69.3% in FY2024, and net income grew an astounding 635.3%, the GLP-1 setback introduces a significant headwind that could temper these figures in the coming quarters. The market's initial enthusiasm for HIMS's GLP-1 play, which saw the stock bid up multiple times in 2025, has now given way to a more cautious, risk-averse stance.

Is HIMS's Diversification Strategy a Viable Lifeline?

In response to the GLP-1 setback, Hims & Hers is actively pivoting its strategy, emphasizing diversification into new health segments like longevity and diagnostics, including hormone therapy and multi-cancer testing. This strategic shift aims to reduce dependence on a single drug class and build a more resilient, diversified subscription base over time. The company's existing telehealth infrastructure, pharmacy capacity, and lab integrations provide a solid foundation to expand into these new categories without starting from scratch.

Recent news highlights HIMS's acceleration of AI-driven preventive care, including new menopause and low testosterone treatments, alongside multi-cancer testing. The planned acquisition of Australian digital health firm Eucalyptus, announced on February 19, 2026, is another bold move, projected to add $450 million in annual revenue growing at a triple-digit rate. This international expansion into a broader wellness platform could help offset some of the domestic pressures from the GLP-1 controversy and broaden its total addressable market.

However, these new ventures come with their own set of regulatory and clinical expectations. While they may be less directly tied to the GLP-1 controversy, they still require significant investment in compliance, clinical validation, and market penetration. The key question for investors is whether these new categories can meaningfully offset the pressure in weight management and whether HIMS can build durable, compliant businesses in these segments. The company's ability to execute on this diversification, while simultaneously managing ongoing legal and regulatory challenges, will be critical for its long-term success.

What Does This Mean for Investors in HIMS?

For investors, the current situation with Hims & Hers presents a complex risk-reward profile, characterized by high volatility and significant uncertainty. The stock's current price of $15.63 is near its 52-week low of $15.29, a stark contrast to its 52-week high of $72.98. This substantial decline reflects the market's repricing of HIMS in light of the GLP-1 controversy. While the consensus analyst price target is $39.56, with a median of $37.00, these targets were likely set before the full extent of the GLP-1 legal and regulatory issues became clear.

The analyst rating consensus for HIMS is currently "Hold" from 17 analysts, with 10 holding this view, 5 recommending Buy, and 2 recommending Sell. This mixed sentiment underscores the divergent opinions on the stock's future. The company's high Beta of 2.47 indicates its shares are significantly more volatile than the broader market, making it a higher-risk investment. Investors should closely monitor the progress of the Novo Nordisk lawsuit and any further FDA actions, as these will be key determinants of HIMS's operational flexibility and financial health.

On the bullish side, HIMS still boasts a strong direct-to-consumer brand, a robust subscription model with 2.4 million subscribers by Q1 2025, and a wide total addressable market in telehealth. Its efficiency metrics, such as a 75.0% gross margin and 6.1% net margin (TTM), demonstrate a profitable core business. However, the immediate future will be a year of transition, where regulatory risks are more visible. The path back to sustained high growth without reliance on contentious compounded GLP-1 drugs will require clear execution and vision from management, particularly in scaling its new longevity and diagnostic offerings.

The Hims & Hers story is far from over, but the GLP-1 setback has fundamentally altered its risk profile and growth narrative. Investors should brace for continued volatility, closely track legal and regulatory developments, and assess the company's ability to successfully pivot and scale its diversified offerings to regain its footing in the competitive telehealth landscape.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.